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Objective: To assess the course of sexual function in epilepsy patients treated with
lamotrigine.
Material and methods: This open study included 141 patients treated with lamo-
trigine for a period of 8 months: 79 patients initiated treatment with lamotrigine
monotherapy, and 62 were switched to lamotrigine because of lack of efficacy or
adverse events to a previous antiepileptic drug (AED). Patients were assessed at
baseline and after 4 and 8 months of treatment. In the baseline and final visits the
Changes in Sexual Functioning Questionnaire (CSFQ) was applied. Analysis was
performed in an intent-to-treat population.
Results: In women who started treatment with lamotrigine, a significant improve-
ment was observed, both in total CSFQ score (increase of 5.39  6.95 points;
p < 0.05), and in the five dimensions of the scale (desire/frequency, desire/interest,
pleasure, arousal/excitement and orgasm). In men, a significant improvement was
only observed in the pleasure dimension. In the group of patients in whom a previous
AED was substituted by lamotrigine, significant improvement was recorded in the
dimensions of pleasure and orgasm in men and desire/frequency in women, whilst in
women the desire/interest dimension showed a decrease.
Conclusions: In this observational study, an improvement in sexual dysfunction was
observed in association with lamotrigine. This could have been the result of improve-
ment of the epilepsy, changes in quality of life, elimination of side effects from other
AEDs, or a mood-stabilizing effect of lamotrigine.
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An increased risk for sexual and reproductive dys-
function has been well-documented in patients with
epilepsy. These deficiencies have a deleterious
impact in the patient’s quality of life, and include
diminished libido, dyspareunia, erectile dysfunc-
tion, and lack of sexual satisfaction.1—3 In women
with epilepsy, irregularities of the menstrual cycle,
anovulatory cycles, and polycystic ovaries are more
frequent than in the general population;4 in men
with temporal lobe epilepsy increases in the inci-
dence of reproductive endocrine disorders, such as
hypogonadism and hyperprolactinemia, have been
reported.5 Sexual dysfunction can be related to
recurrent seizures, the etiology of epilepsy, and
associated psychological disorders. In addition,
antiepileptic drugs (AEDs) can also impair sexual
and reproductive function. Thus, in some studies
the use of valproic acid has been associated with the
development of polycystic ovaries in women6 and
reduced testicular volume in men7 while phenytoin,
carbamazepine, and barbiturates, have been asso-
ciated with erectile dysfunction and reduced
libido.8 Because of this, it has been postulated that
a change of AED could improve sexual function in
affected patients. However, at the present time
there are no reliable data on which drugs are least
likely to affect sexual function.
Lamotrigine is an extended-spectrum antiepilep-
tic agent approved for use, in monotherapy and
association therapy, for the treatment of focal and
generalized epilepsies in adults and children.9—11
Several lines of evidence suggest that, compared
to some other AEDs, lamotrigine is associated with
a lower risk of causing sexual dysfunction. First, some
studies have shown a lower incidence of hormonal
alterations and polycystic ovarian syndrome in
women who took lamotrigine in comparison to
women treated with valproic acid.12 Second, lamo-
trigine does not induce cytochrome P-450 enzymes, a
mechanism that has been related to endocrine
changes leading to sexual and reproductive dysfunc-
tion.3 And third, published case reports suggest an
improvement in sexual dysfunction at least in some
patients who were switched to lamotrigine.13 The
aim of this study is to assess sexual function in
patients with epilepsy treated with lamotrigine.Methods
Subjects
Participants in this open, prospective, and multi-
centre study were 280 adults (age 18 years) withepilepsy, followed for an 8-month period at various
epilepsy clinics in Spain. Included patients received
lamotrigine as a first treatment for epilepsy
(n = 156), or were switched to lamotrigine mono-
therapy after treatment with another AED failed to
control seizures or were associated with intolerable
adverse events (n = 124). Patients were considered
uncontrolled when they had one or more seizures
with impairment of consciousness after attaining
steady state with an AED at the clinically recom-
mended maintenance dosage. Excluded from the
study were pregnant or breastfeeding women,
patients with serious hepatic or renal disorders,
patients with malignancies or untreated endocrine
disorders (hypogonadism, hypothyroidism or hypo-
pituitarism), patients with psychiatric and cardiac
disorders that prevented regular sexual activity or
substantially modified sexual response, patients
with hypersensitivity to lamotrigine or any of its
vehicles, and those who received medication that
could induce modifications in sexual function in
the 3 months prior to the study period or during
it. Drugs considered to potentially have an effect on
sexual function were antidepressants, antipsycho-
tics, anxiolytics, benzodiazepines, beta-adrenergic
antagonists, thiazide diuretics, some antacids
(cimetidine and ranitidine), digoxin, methyldopa,
non-steroidal anti-inflammatory agents, guanethi-
dine, and progestogens. All participants in the
study, having been informed in detail about its
objectives, gave consent for their inclusion.
Of 280 patients recruited, 141 were assessed at
the last study visit (visit 2), so that this was the
sample used in the intent-to-treat analysis. A total
of 135 were excluded because of personal reasons,
withdrawal of consent, or failure to attend the
second visit, and 4 were excluded because of pro-
tocol violation. The 141 patients who completed the
study were analysed separately in two groups: group
A (n = 79) included those who were not receiving
AED treatment and started lamotrigine monother-
apy; group B (n = 62) included patients treated with
another AED who were changed to lamotrigine
monotherapy either because of poor efficacy or
adverse events to the previous AED. Within group
B, 23 patients were receiving valproate, 18 carba-
mazepine, 9 phenytoin, 4 topiramate, 3 oxcarbaze-
pine, 2 primidone, 2 clonazepam, and 1 phenob-
arbital. There was no difference in age among
groups: mean 36.24  14.51 years for group A and
38.17  13.03 years for group B. Dosages of lamo-
trigine were the customary ones in clinical practice,
both in monotherapy (incremental doses from
25 mg/day for 4 weeks, up to a maintenance dose
of 100—200 mg/day), and in substitutive therapy. In
the latter case, if the previous AED was carbama-
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the initial dose of lamotrigine was 50 mg/day for
2 weeks, followed by 100 mg/day for the following 2
weeks and 200 mg/day during Weeks 5 and 6. From
Week 7 the dosage of lamotrigine was maintained
and the withdrawal of the initial drug was com-
pleted over the following 4 weeks.When the original
drug was valproate, the initial dose of lamotrigine
was 12.5 mg/day (or 25 mg on alternate days) for
the first 2 weeks, followed by 25 mg/day for the
following 2 weeks and 50 mg, twice a day, during
Weeks 5 and 6. Reduction of valproate began in
Week 7, at a rate of 200—500 mg per week, in Week
8 the dosage of lamotrigine was increased to
150 mg/day, and finally, in Week 10 to 200 mg/
day. In patients treated with clonazepam, oxcarba-
zepine, or topiramate, lamotrigine was initiated in a
similar schedule as in monotherapy, and the discon-
tinuation of the prior AED completed in the follow-
ing 4 weeks.
Measures
Patients were monitored over a period of 8 months,
in which they were assessed on three occasions:
baseline, visit 1 (4 months), and visit 2 (8 months).
On each occasion they underwent a physical exam-
ination, in which their weight, height, and blood
pressure were measured, and the frequency and
type of their epileptic seizures recorded. Sexual
function was assessed using the Changes in Sexual
Functioning Questionnaire (CSFQ) both during base-
line and at the final visit. The CSFQ was developed
by Clayton et al.14 to monitor changes in patients’
sexual functioning, as a result of illness, medica-
tion, or both. A Spanish validation of this question-
naire was developed by Bobes et al.15 The 14 items
in the brief version of the questionnaire are grouped
in five dimensions (desire/frequency, desire/inter-
est, pleasure, arousal/excitement, and orgasm),
and scored on a 5-point Likert-type scale, where
1 is the poorest rating (never, no enjoyment) and 5
the best (daily, a lot). The scale can be self- or
physician-applied, and application time is usually
15—20 min. A total score is obtained, as well as
scores for each of the five subscales or dimensions.
Total score is obtained by adding up the scores in the
12 items making up the scale proper, plus those in 2
extra items (related to arousal and painful
orgasms), so that total score can range from 14 to
70. Cut-off points proposed by the authors for dif-
ferentiating between problems and absence of pro-
blems are desire/frequency, men 8, women 6;
desire/interest, men 11, women 9; pleasure, 4 in
both sexes; arousal/excitement, men 13, women12; orgasm, men 13, women 11; and global sexual
function, men 47, women 41.
In order to complete the information related to
sexual function in patients with epilepsy, they were
asked a series of specific questions: lack of sexual
interest (never, rarely, sometimes, often, always);
relation between lack of interest and the illness (not
related, partially related, totally related); and rela-
tion between lack of interest and antiepileptic
medication (not related, partially related, totally
related).
Statistical analysis
An intent-to-treat data analysis was carried out,
using, as a tool for interpreting lost values, the
last-observation-carried-forward (LOCF) method,
taking into account all the patients with baseline
assessment and at least one more, even if they did
not complete the full study period. Quantitative
data were expressed through mean and standard
deviation, and categorical variables were described
by means of absolute and relative frequencies. For
comparisons of the quantitative variables, we used
the Student’s t-test, and for comparisons between
the categorical variables, the chi-squared test with
Pearson modification. Between-group comparisons
of the quantitative variables weremade bymeans of
covariance analysis (ANCOVA). The statistical sig-
nificance criterion was set at p < 0.05. SAS system
package, Version 8.02 (SAS Institute, Inc., Cary, NC,
USA) was used for statistical analysis.Results
Table 1 shows the most relevant demographic data
of the patients participating in the study. In group A
54% patients were single, compared to a predomi-
nance of married (or cohabitational) patients in
group B (56%). The anthropometric parameters at
the beginning of the study (average weight
70.79  12.21 kg; waist—hip ratio 0.83  0.09)
were within the normal range for this population,
as were the blood pressure values (systolic pres-
sure/diastolic pressure: 125.35  15.73 mmHg/
73.58  9.53 mmHg).
Tables 2 and 3 show the mean scores obtained in
the CSFQ (mean score for the different dimensions
and total score for the questionnaire) for the base-
line visit and final visit (month 8), according to sex,
and for patients who began their treatment with
lamotrigine (group A, Table 2) and those in whom
their AED was substituted by lamotrigine (group B,
Table 3). Some questions (four or less in each case)
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Table 1 Demographic, anthropometric, and clinical data
Group A Group B Total
n 79 62 141
Age (year) 36.24  14.51 38.17  13.02 37.09  13.86
Sex
Men 43 (45%) 32 (52%) 75 (53%)
Women 36 (55%) 30 (48%) 66 (47%)
Height (cm) 171.08  8.05 168.92  8.55 170.10  8.32
Weight (kg) 71.72  12.51 69.69  11.85 70.79  12.21
SBP (mmHg) 124.26  16.48 126.83  14.68 125.35  15.73
DBP (mmHg) 73.06  9.63 74.28  9.44 73.58  9.53
Smoking 57 (72%) 42 (65%) 97 (69%)
Seizure type
Simple partial 37/79 (47%) 23/62 (37%) 60/141 (43%)
Complex partial 42/79 (53%) 49/62 (79%) 91/141 (64%)
Secondary GTC 43/79 (55%) 35/62 (57%) 78/141 (56%)
Primary GTC 57/79 (73%) 27/62 (44%) 84/141 (60%)
Typical absence 0 4/62 (7%) 4/141 (3%)
Myoclonic 4/79 (5%) 5/62 (8%) 9/141 (6%)
Unclassified 7/79 (9%) 4/62 (7%) 11/141 (8%)
Group A, patients beginning their treatment with lamotrigine; group B, patients whose previous AED was substituted by lamotrigine.
SBP, systolic blood pressure; DBP, diastolic blood pressure; and GTC, generalised tonic clonic.
Figure 1 Total score in the CSFQ in sexual function. Solid
line, patients beginning their treatment with lamotrigine
(group A); dotted line, patients whose AED was substi-
tuted by lamotrigine. *p < 0.05 final visit vs. baseline
(group B).were not answered by four patients in group A and
three in group B, and these were excluded in some
analysis (Tables 2 and 3). According to the cut-off
points, problems of sexual function in all five dimen-
sions were observed at baseline. In group A (patients
who initiated therapy with lamotrigine in monother-
apy), the total CSFQ score increased by 5.39  6.95
points (CI 95%; 2.84—7.94; p < 0.05) in the subgroup
of women (12% with respect to baseline) (Fig. 1). In
addition, this group also presented a significant
improvement ( p < 0.05) in all the CSFQ dimensions
(desire/frequency, desire/interest, pleasure, arou-
sal/excitement, orgasm) (Table 2). On the contrary,
in the men’s subgroup total score increased by
1.12  4.65 points (CI 95% ; 2.84—7.94) (2%), a
difference that was not statistically significant
( p = 0.1306) (Fig. 1); however, significant differ-Table 2 Changes in Sexual Functioning Questionnaire (CSFQ) abbreviated, according to sex, in 75 patientsa beginning
their treatment with lamotrigine
Dimensions Men (n = 42) Women (n = 33)
Baseline Final visit Baseline Final visit
Desire/frequency 7.07  1.18 7.26  1.13 5.62  1.44 6.36  1.48 *
Desire/interest 9.81  2.29 10.00  2.05 6.50  2.08 7.52  2.44 *
Pleasure 3.45  0.77 3.76  0.79 * 3.12  0.91 3.45  0.94 *
Arousal/excitement 11.52  2.14 11.90  1.59 8.82  2.45 9.88  2.16 *
Orgasm 11.33  1.66 11.57  1.71 8.91  2.80 10.24  2.22 *
Total score 52.74  6.59 53.91  5.71 40.85  8.22 45.58  7.71 *
a Four patients of 79 did not answer some questions of the questionnaire and are not included.
* p < 0.05 final visit vs. baseline.
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Table 3 Changes in Sexual Functioning Questionnaire (CSFQ) abbreviated, according to sex, in 59 patientsa whose
AED was substituted by lamotrigine
Dimensions Men (n = 32) Women (n = 27)
Baseline Final visit Baseline Final visit
Desire/frequency 6.97  1.06 7.25  0.84 5.79  1.53 6.22  1.48 *
Desire/interest 9.65  2.41 9.93  2.24 6.76  7.88 2.29  2.78 *
Pleasure 3.22  0.71 3.62  0.55 * 2.86  0.83 3.04  0.85
Arousal/excitement 10.84  2.66 11.41  2.15 9.07  2.23 8.92  2.48
Orgasm 10.25  2.21 11.28  1.94 * 9.10  2.59 9.37  2.50
Total score 50.06  8.22 52.38  7.29 41.41  8.53 43.30  9.72
a Three patients of 62 did not answer some questions of the questionnaire and are not included.
* p < 0.05 final visit vs. baseline.ences were observed in the pleasure dimension
(Table 2). In group B (patients in whom a previous
AED was substituted by lamotrigine monotherapy),
total CSFQ score increased, both in men
(2.31  6.52 points, CI 95%; 0.04 to 4.66) and in
women (2.48  7.06 points, CI 95%; 0.31 to 5.27),
and to a similar extent in both sexes (5% in each),
even though there were no statistically significant
differences in either of the two subgroups (Fig. 1;
Table 3). Significant improvements were only
observed (p < 0.05) in some dimensions, such as
pleasure and orgasm in men and desire/frequency in
women. In the latter, a significant decrease in the
score for the desire/interest dimension was
observed (Table 3). The cut-off point of the scale
was only surpassed, at the end of the treatment, for
differentiating the absence of problems in the
women’s subgroup for the desire/frequency dimen-




Lack of sexual interest
Never 24/79 (30%) 26/7
Rarely 21/79 (27%) 28/7
Sometimes 18/79 (23%) 15/7
Often 12/79 (15%) 7/79
Always 4/79 (5%) 3/79
Is the lack of sexual interest related to the illness?
Not related 51/73 (70%) 53/7
Partially related 18/73 (25%) 22/7
Totally related 4/73 (5%) 0/75
Is the lack of sexual interest caused by the antiepileptic m
Not related — 66/7
Partially related — 9/75
Totally related — 0/75
Group A, patients beginning their treatment with lamotrigine; grou
* p < 0.05 group A vs. group B (final visit).The difference in total CSFQ score between
groups A and B was 0.17 points (CI 95%; 2.42
to 2.08) in men and 2.90 points (CI 95%; 0.49 to
6.29) in women, with no statistically significant
differences in either case. Nevertheless, in the
subgroup of women, significant differences were
obtained in two dimensions of the CSFQ (arousal/
excitement, p = 0.0106; and orgasm, p = 0.0426),
which showed higher scores in group A. On the other
hand, no significant differences were found for
changes in the CSFQ score in the analysis of the
subgroups of patients who substituted carbamaze-
pine or valproate by lamotrigine, either between
them or with respect to group A.
Table 4 shows the results for the three specific
questions on sexual function and epilepsy that all
participants were asked. Here, patients showed,
though in an irregular way, a certain subjective lack
of sexual interest (group A and group B scored in thetween lack of sexual interest, epilepsy, and antiepileptic
Group B
visit Baseline Final visit
9 (33%) 11/58 (11%) 15/62 (24%)
9 (35%) 15/58 (26%) 26/62 (42%)
9 (19%) 18/58 (31%) 16/62 (26%)
(9%) 13/58 (22%) 4/62 (6%)
(4%) 1/58 (2%) 1/62 (2%)
5 (71%) 24/54 (44%) 31/55 (56%)
5 (29%) 27/54 (50%) 23/55 (42%)
(0%) 3/54 (6%) 1/55 (2%)
edication? *
5 (88%) 27/54 (50%) 40/55 (73%)
(12%) 20/54 (37%) 14/55 (25%)
(0%) 7/54 (13%) 1/55 (2%)
p B, patients whose AED was substituted by lamotrigine.
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Figure 2 Percentage of patients free of epileptic seizures at final visit. *p < 0.05 group A vs. group B.range ‘‘sometimes’’—‘‘always’’ in proportions of 54
and 55%, respectively, at the beginning of the
study), though the majority of the untreated
patients did not associate this directly with the
illness (70%)–—in contrast to patients treated pre-
viously with an AED, 56% of whom linked this lack of
interest, at least partially, to the epilepsy. In the
final visit of the study, a significantly higher percen-
tage of patients treated initially with lamotrigine
believed that their lack of sexual interest was not
caused by antiepileptic medication (88% in group A
versus 73% in group B, p = 0.0461). The most marked
differences in this respect were obtained in the
subgroup of patients initially treated with carbama-
zepine (60%, p = 0.0164, compared to group A).
Finally, a significant difference between group A
and B was also found in the rate of patients that
achieved complete seizure control (Fig. 2). Seventy-
nine percent of patients in group A were seizure-
free at the end of the study, compared to 45% in
group B ( p < 0.05).Discussion
A combination of factors can explain the higher
incidence of sexual function alterations in patients
with epilepsy compared to the general popula-
tion.1—3 Social isolation, the social stigma asso-
ciated with epilepsy, low self-esteem, and a
higher incidence of depression among patients with
epilepsy have a negative influence on the search for
a partner, and may play a role in the appearance of
sexual dysfunction. Physiological mechanisms also
affect sexual function; epileptiform activity fre-quently originates or propagates to the limbic sys-
tem, and some studies have found a higher
prevalence of sexual dysfunction in patients with
temporal lobe epilepsy compared to other epilep-
sies not involving the limbic system.5 Moreover,
improvement in sexual function has been observed
in these patients when they attain complete seizure
control after temporal lobectomy.16 In addition,
seizures and interictal activity may interfere the
functioning of the hypothalamus—hypophysis—adre-
nal axis, giving rise to an anomalous secretion of
sexual hormones. Indeed, some epileptic seizures
provoke an increase in the secretion of prolactin,
and excess of prolactin is known to cause diminished
libido and impotence.17 Similarly, increased levels
of prolactin have been reported after generalized
tonic—clonic seizures,18 in relation to complex par-
tial seizures in which the limbic system is acti-
vated,19 and spontaneously during sleep in
patients with partial epilepsy, without direct rela-
tion to the occurrence of seizures.20 Hormonal
changes and variations in the expression of neuronal
receptors and ion channels through the life cycle
influence the onset and remission of certain epilep-
sies such as some idiopathic generalized epilepsies
and benign focal epilepsies of childhood.21 Numer-
ous studies demonstrate the epileptogenic effect of
estrogens in experimental animals and humans, as
well as the protective effect of progestogens against
seizures,22 mechanisms that explain in part the
occurrence of catamenial epilepsy.
Finally, AEDs may also interfere with sexual func-
tion.3 Drugs that induce the cytochrome P-450
enzyme system, such as carbamazepine, barbitu-
rates, and hydantoines, can cause reduced libido
148 A. Gil-Nagel et al.and erectile dysfunction. The mechanisms of these
side effects are not known; they could be related to
a decrease in total testosterone levels due to its
increased clearance by the enzymes of the P-450
complex,3 a reduction of free testosterone levels
caused by an increase in plasma concentration of
globulins, to which sex hormones bind,23 or an
induction of aromatase, converting free testoster-
one to estradiol.24,25 In fact, in patients treated
with carbamazepine and phenytoin total testoster-
one levels do not tend to be lower than those of the
general population, but levels of freely circulating
testosterone are indeed inferior.26 Since lamotrigine
does not induce or inhibit isoenzymes of the P-450
hepatic microsomal complex, it has been argued
that this drug is less likely to cause sexual dysfunc-
tion. Evidence to support this claim is still scarce;
Husain et al. report a series of three men with
epilepsy in whom lamotrigine had a favourable
effect on sexual dysfunction, including one case
in which impotence resolved when the dose of
carbamazepine was reduced and lamotrigine
increased.13 Furthermore, a recent study27 showed
that sexual function, bioactive testosterone levels,
hormonal ratio (testosterone/estradiol), and gona-
dal efficiency (bioactive testosterone/luteinizing
hormone) are better or higher in patients treated
with lamotrigine than in those treated with enzyme-
inducing AEDs. In our study, the highest proportion
of patients who associated lack of sexual interest
with antiepileptic medication was observed in the
subgroup of patients initially treated with carbama-
zepine. In addition, significant improvements were
observed in some parameters of sexual functioning,
such as pleasure and orgasm, in men treated with
other AEDs when these were substituted by lamo-
trigine.
The CSFQ has been employed mostly in the field
of mental health,28,29 and there are no published
works on its application in patients with epilepsy.
The present study contributes some data in this
regard, showing that lamotrigine might have a posi-
tive effect on the sexual dysfunction presented by
epileptic patients who start their treatment with
this drug, and particularly in the case of women, as
indicated by a statistically significant increase in
CSFQ score. On the other hand, in the group of
patients in which other AEDs were substituted by
lamotrigine, while there was an increase in CSFQ
score, it was not statistically significant. This dif-
ference among both groups could have several
explanations. It is possible that a longer ‘‘wash-
out’’ period is necessary in order to eliminate the
deleterious effect of some AEDs on sexual function.
In this sense, Herzog et al.28 note that in patients
with chronic epilepsy treated long-term withenzyme-inducing AEDs, the effect of these drugs
on sexual hormones, once the therapy is inter-
rupted, is not sufficiently established yet. There-
fore, the period analyzed in this study may not have
been long enough to obtain significant improve-
ments in group B, particularly considering that
the time required for full cessation of administra-
tion of the first AED is more than 2 months. While
this possibility could explain the lack of effect on
group B, it does not give any information on the
positive effect observed in patients who receive
lamotrigine monotherapy as the first treatment
(group A); in this group the improvement in sexual
function may be related to an improvement in
seizure control, supported by the observation of a
higher number of patients who became seizure-free
in group A compared to group B. A second explana-
tion could be an improvement in mood, other psy-
chological factors, or quality of life as a result of an
improvement in their clinical condition. Finally,
these results may have been related to a mood-
stabilizing effect of lamotrigine.30 In any case,
because this is an open exploratory study, in which
not all variables could be controlled, these results
should be judged with caution, keeping in mind that
a whole host of other factors (psychological, social,
environmental, cultural, etc.) also intervene in sex-
ual functioning, conditioning the response of each
individual.Conclusions
Concluding, and taking into account the limitations
of this open study, we can state that an improve-
ment in sexual function can be observed in some
patients with epilepsy treated with lamotrigine,
especially in women beginning their antiepileptic
treatment with this drug. This can be the result of
decreased seizures and side effects from other
AEDs, improvement in quality of life, or a mood-
stabilizing effect of lamotrigine. In addition, it is
possible that the CSFQ could be a useful tool to
explore sexual function in both men and women
with epilepsy. These results can serve to open the
door to new comparative research, of a controlled
nature, with larger samples and longer follow-up
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